SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nanobiotix Reports 41.7% Response Rate in Phase 1 Melanoma Trial

Nanobiotix reported a 41.7% response rate in a Phase 1 trial of its NBTXR3 combination for resistant melanoma.

Related stories